Integer Expands R&D and Coating Capabilities at MD&M West 2026
Event summary
- Integer Holdings Corporation will exhibit at MD&M West 2026 (Feb. 3–5) in Anaheim, California, showcasing its expanded 20 x 50 sq. ft. booth (#3201).
- The company will highlight its R&D Velocity ecosystem, which integrates design, prototyping, and manufacturing to accelerate medical device development.
- Integer will showcase its expanded medical coatings portfolio, including PTFE, hydrophilic coatings, parylene, and advanced surface-modification technologies.
- Recent acquisitions of Precision Coating, VSi Parylene, and certain Biocoat assets have strengthened Integer's position as a fully integrated coating partner.
The big picture
Integer's expanded capabilities at MD&M West 2026 reflect the growing trend of medical device contract manufacturers offering end-to-end solutions. The company's recent acquisitions and focus on integrated R&D align with the industry's push for faster, more efficient product development. As a key player in the cardiac rhythm management, neuromodulation, and cardio and vascular markets, Integer's strategic moves could influence the broader CDMO landscape.
What we're watching
- Integration Success
- How Integer will leverage its recent acquisitions to streamline its coatings business and enhance its end-to-end solutions.
- Market Differentiation
- Whether Integer's R&D Velocity ecosystem can provide a competitive edge in the crowded medical device CDMO space.
- Customer Adoption
- The pace at which medical device companies adopt Integer's integrated R&D and coating solutions to accelerate their product development cycles.
Related topics